Please assess the completion status of the following clinical trial:

Trial Title: Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients much have histologically confirmed adenocarcinoma of the colon or rectum.~* Patients must have measurable recurrence or metastases in the liver and/or lungs.~* Patients must have prior chemotherapy for advanced colorectal cancer and have previously received both an oxaliplatin and an irinotecan based regimen.~* Age \> 18 years.~* Life expectancy greater than 4 weeks.~* ECOG performance status \<3.~* Patients must have normal organ and marrow function.~* Patients must be able to swallow capsules.~* Patients must be able to understand and willing to sign a written informed consent document.~* Patients are included regardless of KRAS/BRAF status.~Exclusion Criteria:~* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.~* Patients may not be receiving any other investigational agent.~* Patients with know brain metastases should be excluded from this clinical trial because they often develop progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to quinacrine, capecitabine or fluorouracil.~* The concomitant use of quinacrine and primaquine is contraindicated.~* Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Pregnant women are excluded from this study.~* Patients with a baseline creatinine clearance of \< 50 mL/min.~* Patients must be currently not treated with quinacrine or drugs related to quinacrine.~* Patients who require anti-arrhythmic treatment with amiodarone or any drug with a quinidine-like effect on the heart or who have history of a malignant ventricular arrhythmia unless they have a functioning automatic implantable cardio defibrillator implanted.~* Patients who have a history of noninfectious hepatitis or alcoholism.~* Patients with a lifetime history of porphyria or psoriasis because it can exacerbate these conditions.~* Patients with documented glucose-6-phosphate dehydrogenase deficiency.~* Patients with a lifetime history of seizure disorder.~* Patients with a lifetime history of dermatitis as an allergic/toxic reaction to any medication.~* Patients with know dihydropyrimidine dehydrogenase deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I Level -2 (Type: EXPERIMENTAL): Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg once per day (days 1-21) for a 21 day cycle
- Phase I Level -1 (Type: EXPERIMENTAL): Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle
- Phase I Level 0 (Type: EXPERIMENTAL): Group 3: capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), quinacrine at a dose of 200 mg twice a day (days 1-21) for a 21 day cycle
- Phase II (Type: EXPERIMENTAL): Phase II will use the treatment outlined in phase I, using the recommended phase II dose (RP2D) derived from Phase I.~Patients will receive capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval